Publications by authors named "Fernanda Damian"

Claim this Profile
A
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P Brungs, Hayden Christie, Fernanda Damian

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
Fernanda Bronzon Damian, Andreia Cristina De Melo, Graziela Z Dal Molin, Angélica Nogueira-Rodrigues, Aknar Calabrich

Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Domenica Lorusso, Ana Oaknin, Giuliano S Borges, Fernanda Damian, Nelleke Ottevanger

Gynecol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Fernanda Damian

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Luis Fein, Nicolas Lazaretti, Yamil López Chuken, J Rogelio González Ramírez Benfield, Max S Mano, Fernanda Damian

Clin Drug Investig· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Luis Fein, Nicolas Lazaretti, Yamil López Chuken, J Rogelio González Ramírez Benfield, Max S Mano, Fernanda Damian

Clin Drug Investig· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Ana Oaknin, Bradley J Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Fernanda Damian

Eur J Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215).
Angélica Nogueira Rodrigues, Andréia Cristina de Melo, Aknar Freire de Carvalho Calabrich, Eduardo Cronenberger, Kátia Luz Torres, Fernanda Damian

Int J Gynecol Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of hydronephrosis and kidney function on survival in newly diagnosed advanced cervical cancer.
Fernanda Bronzon Damian, Fernando Kude de Almeida, Fernando Schmidt Fernandes, Mirela Foresti Jimenez

Gynecol Oncol Rep· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with Cemiplimab in Recurrent Cervical Cancer.
Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, Austin Miller, Andreia C de Melo, Fernanda Damian

N Engl J Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis